Ingevity Q3 sales fall on Road Markings divestiture

By Reuters News


Overview

  • US specialty materials firm's Q3 sales fell 8% yr/yr, mainly due to Road Markings divestiture

  • Q3 net income and adjusted EPS rose from prior year

  • Company repurchased $39 mln in shares during Q3


Outlook

  • Ingevity narrows 2026 adjusted EBITDA outlook to $385 mln–$395 mln, maintaining midpoint

  • Company expects 2026 net sales of about $1.1 bln and diluted adjusted EPS of $5.25–$5.45

  • Free cash flow for 2026 seen at $220 mln–$230 mln, excluding litigation settlement payment


Result Drivers

  • ROAD MARKINGS DIVESTITURE - Co said sales fell 8% yr/yr primarily due to the April 2026 sale of the Road Markings product line

  • PERFORMANCE MATERIALS DEMAND - Resilient North American demand for Performance Materials, supported by hybrid vehicle trends and higher filtration sales, offset lower volumes in China and Europe

  • PAVEMENT TECHNOLOGIES PRESSURE - Softer demand and higher input and logistics costs weighed on Pavement Technologies segment results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Slight Beat*

$305.10 mln

$304.60 mln (2 Analysts)

Q3 EPS from Continuing Operations

$1.46

Q3 Adjusted EPS

$1.63

Q3 Net Income from Continuing Operations

$51.1 mln

Q3 Gross Profit

$132.80 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the diversified chemicals peer group is "buy"

  • Wall Street's median 12-month price target for Ingevity Corporation is $92.00, about 24.9% above its November 3 closing price of $73.63

  • The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 13 three months ago


Reuters Recommended Reads

  • Nov 2 - Celanese Q3 sales rise 6%

  • Nov 2 - Chemours Q3 adjusted profit misses estimates despite titanium pricing gains

  • Nov 4 - AdvanSix Q3 sales rise on higher pricing


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.